The DOI matches its Crossref record; 142 of the 145 references it cites were found in a registry or an index; none of the 155 sources its claims cite is checked for support yet.
Thyroid Hormones and Cardiovascular Function and Diseases
Open accessAbstract
Thyroid hormone (TH) receptors are present in the myocardium and vascular tissue, and minor alterations in TH concentration can affect cardiovascular (CV) physiology. The potential mechanisms that link CV disease with thyroid dysfunction are endothelial dysfunction, changes in blood pressure, myocardial systolic and diastolic dysfunction, and dyslipidemia. In addition, cardiac disease itself may lead to alterations in TH concentrations (notably, low triiodothyronine syndrome) that are associated with higher morbidity and mortality. Experimental data and small clinical trials have suggested a beneficial role of TH in ameliorating CV disease. The aim of this review is to provide clinicians dealing with CV conditions with an overview of the current knowledge of TH perturbations in CV disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 155 cited sources checked · 0 supported · 0 flagged
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The normal negative feedback regulation of thyroid function is disrupted by illness, including conditions such as acute myocardial infarction (AMI) or heart failure (HF), and is characterized by a reduction in serum TH without a concomitant rise in circulating TSH levels”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > MECHANISMS OF TH ACTION PHYSIOLOGY OF THYROID FUNCTION.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“TH levels regulate TRH and TSH production and release (7).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > MECHANISMS OF TH ACTION PHYSIOLOGY OF THYROID FUNCTION.
What the sources say
- Not checked yetcites [7] Larsen, 1982, Thyroid-pituitary interaction: feedback regulation of thyrotropin secretion by thyroid hormones, N Engl J Med source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Two subsequent trials suggested that the reduction of LDL-C was approximately 0.3 mmol/l (11.6 mg/dl) (16,41).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > THYROID DISEASE AND CV RISK FACTORS
What the sources say
- Not checked yetcites [16] Razvi, 2007, The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial, J Clin Endocrinol Metab source
- Not checked yetcites [41] Iqbal, 2006, Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromsø Study, J Intern Med source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Similar effects are observed when patients with chronic HF are treated with intravenous T 3 (18).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
What the sources say
- Not checked yetcites [18] Pingitore, 2008, Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study, J Clin Endocrinol Metab source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“is supported by the association of low serum T 3 levels with the presence of cardiac fibrosis in patients with idiopathic dilated cardiomyopathy (30).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > b1-adrenergic receptor Thyroid hormone receptor a1
What the sources say
- Not checked yetcites [30] Wang, 2016, Free triiodothyronine level correlates with myocardial injury and prognosis in idiopathic dilated cardiomyopathy: evidence from cardiac MRI and SPECT/PET imaging, Sci Rep source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, T 3 has the unique pharmacological properties of an inodilator acting primarily on diastolic dysfunction.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Pulmonary artery hypertension that resolves after return to the euthyroid state has been reported in patients with thyrotoxicosis mainly due to a fall in cardiac output.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, serum TSH is a robust marker of systemic TH status.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > MECHANISMS OF TH ACTION PHYSIOLOGY OF THYROID FUNCTION.
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Thus, an association, if present, is likely to be weak, with SCH contributing to a small increase in serum LDL-C, ranging between 3 and 15 mg/dl (0.1 to 0.4 mmol/l) (42).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > THYROID DISEASE AND CV RISK FACTORS
What the sources say
- Not checked yetcites [42] Tanis, 1996, Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies, Clin Endocrinol (Oxf) source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“the antifibrotic effect of TH is also linked to the T 3 -induced inhibition of profibrotic pathways, (29)”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > b1-adrenergic receptor Thyroid hormone receptor a1
What the sources say
- Not checked yetcites [29] van Rooij, 2009, A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance, Dev Cell source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 60
- Probably not a substantial claim. 9
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Hyperthyroidism reduces cholesterol levels, which are reversed when euthyroidism is achieved.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > THYROID DISEASE AND CV RISK FACTORS
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Furthermore, some studies have shown SHyper patients to have increased carotid intima-media thickness and carotid artery plaques (48,49), although this was not confirmed in a recent large, population-based study (50).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH, VASCULATURE, AND BLOOD PRESSURE.
What the sources say
- Not checked yetcites [48] Völzke, 2004, Thyroid function and carotid wall thickness, J Clin Endocrinol Metab source
- Not checked yetcites [49] Dörr, 2008, The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area, Eur J Endocrinol source
- Not checked yetcites [50] Delitala, 2015, No evidence of association between subclinical thyroid disorders and common carotid intima medial thickness or atherosclerotic plaque, Nutr Metab Cardiovasc Dis source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies have shown that TH regulates endothelial nitric oxide production and vascular tone”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
What the sources say
- Not checked yetcites [14] Papaioannou, 2004, Treating hypothyroidism improves endothelial function, Metabolism source
- Not checked yetcites [15] Taddei, 2003, Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy, J Clin Endocrinol Metab source
- Not checked yetcites [16] Razvi, 2007, The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial, J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Recurrent ischemia resulting in adverse CV events following optimal treatment for an acute coronary syndrome occurs in approximately 10% of subjects in randomized controlled trials (RCTs) (2), and this number nearly doubles in real-world registries (3).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > Abstract
What the sources say
- Not checked yetcites [2] Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med source
- Not checked yetcites [3] Jernberg, 2015, Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective, Eur Heart J source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The inexorable progress of CV disease, despite optimal guideline-based primary and secondary prevention, suggests a multifactorial etiology and the need to assess other precipitants that may exacerbate existing CV disease.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Hyperthyroidism causes a hyperdynamic circulation, characterized by increased cardiac contractility and heart rate, increased preload, and decreased systemic vascular resistance (SVR), resulting in significantly increased cardiac output.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH, VASCULATURE, AND BLOOD PRESSURE.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Low thyroid function reduces cardiac function and induces morphological, molecular, and structural changes of the myocardium.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > b1-adrenergic receptor Thyroid hormone receptor a1
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Nongenomic effects are usually receptor-independent and largely occur at the plasma membrane, regulating ion transporter activity (10).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
What the sources say
- Not checked yetcites [10] Davis, 2016, Nongenomic actions of thyroid hormone, Nat Rev Endocrinol source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, optimal myocyte gene expression remains dependent on serum T 3 levels, and if they fall, despite the fact that TSH and T 4 levels may be normal, the heart will express a hypothyroid phenotype.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In mammals, these receptor proteins exist in 2 isoforms, a and b (TRa and TRb), and bind to TH response elements in the promoter regions of THresponsive genes.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Lipoprotein(a), a more potent marker of atherogenesis, also increases in overt hypothyroidism and decreases with TH replacement (35,36).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > THYROID DISEASE AND CV RISK FACTORS
What the sources say
- Not checked yetcites [35] Tzotzas, 2000, Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment, Thyroid source
- Not checked yetcites [36] Martinez-Triguero, 1998, Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism, Mayo Clin Proc source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Although hyperthyroidism can increase systolic blood pressure, the net effect is dependent on the balance between increased cardiac output and decreased SVR (43,44).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH, VASCULATURE, AND BLOOD PRESSURE.
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Patients who are overtly hypo-or hyperthyroid show CV and hematologic manifestations that are well-documented, and both can, if left untreated, accelerate the onset of symptomatic CV disease.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A Cochrane review of 6 RCTs concluded that levothyroxine treatment of SCH had no overall effect in reducing total cholesterol, but suggested a trend toward reducing LDL cholesterol (LDL-C) levels >155 mg/dl in a subgroup analysis (40).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > THYROID DISEASE AND CV RISK FACTORS
What the sources say
- Not checked yetcites [40] Villar, 2007, Thyroid hormone replacement for subclinical hypothyroidism, Cochrane Database Syst Rev
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Nevertheless, thyroid disease, both overt and subclinical, is a global burden and associated with increased CV disease.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Hyperlipidemia in hypothyroidism is due to a decrease in LDL receptors, resulting in reduced cholesterol clearance from the liver and decreased activity of cholesterol 7a-hydroxylase, which is activated by TH, in breaking down cholesterol (32).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > THYROID DISEASE AND CV RISK FACTORS
What the sources say
- Not checked yetcites [32] Duntas, 2002, Thyroid disease and lipids, Thyroid source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“TRa and TRb activate expression of positively regulated genes in the presence of T 3 and repress expression in its absence.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“patients with hypothyroidism (both overt and subclinical) exhibit impaired endothelial function, which improves with TH replacement therapy (14-16).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH ACTION ON CARDIAC MYOCYTES.
What the sources say
- Not checked yetcites [14] Papaioannou, 2004, Treating hypothyroidism improves endothelial function, Metabolism source
- Not checked yetcites [15] Taddei, 2003, Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy, J Clin Endocrinol Metab source
- Not checked yetcites [16] Razvi, 2007, The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial, J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Low thyroid function also increases peripheral vascular resistance, plasma noradrenaline concentrations, and plasma renin activity, and reduces erythropoietin.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > b1-adrenergic receptor Thyroid hormone receptor a1
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Hypothyroidism is associated with increased oxidation of LDL, which promotes atherogenesis and reverses with treatment (33,34).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > THYROID DISEASE AND CV RISK FACTORS
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Endothelial-dependent vasodilation is lower in overtly hypothyroid and SCH patients (51), and improves with levothyroxine treatment (15,16)”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH, VASCULATURE, AND BLOOD PRESSURE.
What the sources say
- Not checked yetcites [51] Lekakis, 1997, Flow-mediated, endothelium-dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism, and high-normal serum thyrotropin (TSH) values, Thyroid source
- Not checked yetcites [15] Taddei, 2003, Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy, J Clin Endocrinol Metab source
- Not checked yetcites [16] Razvi, 2007, The beneficial effect of l-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial, J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overt and SCH are associated with diastolic hypertension, impaired vascular function, and increased carotid intima hyperplasia (45,47).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH, VASCULATURE, AND BLOOD PRESSURE.
What the sources say
- Not checked yetcites [45] Volzke, 2009, Subclinical hyperthyroidism and blood pressure in a population-based prospective cohort study, Eur J Endocrinol source
- Not checked yetcites [47] Cai, 2011, Blood pressure levels in patients with subclinical thyroid dysfunction: a meta-analysis of cross-sectional data, Hypertens Res source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“T 3 increases systolic depolarization and diastolic repolarization, and decreases the action potential duration, the refractory period of the atrial myocardium, and the atrial/ventricular nodal refractory period.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CARDIOVASCULAR CONSEQUENCES OF OVERT HYPERTHYROIDISM AND SHyper
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Clinical features of this condition are pleural effusion, hepatic congestion, and fluid retention, which can improve with diuretic agents and beta-blockers (75).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CARDIOVASCULAR CONSEQUENCES OF OVERT HYPERTHYROIDISM AND SHyper
What the sources say
- Not checked yetcites [75] Biondi, 2012, Mechanisms in endocrinology: heart failure and thyroid dysfunction, Eur J Endocrinol source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Overt hyperthyroidism has been associated with 16% increased risk of major CV events, mainly due to higher incidence of HF events (74).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CARDIOVASCULAR CONSEQUENCES OF OVERT HYPERTHYROIDISM AND SHyper
What the sources say
- Not checked yetcites [74] Selmer, 2014, Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study, J Clin Endocrinol Metab source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In addition, SCH after admission for an acute cardiac problem has been associated with an up to 3.6-fold increase in cardiac mortality and a 2.3-fold increase in overall death (98).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CV CONSEQUENCES OF OVERT AND SCH
What the sources say
- Not checked yetcites [98] Molinaro, 2012, Persistence of mortality risk in patients with acute cardiac diseases and mild thyroid dysfunction, Am J Med Sci source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overt hypothyroidism is diagnosed when serum TSH is elevated and circulating THs are low and is prevalent in 0.2% to 2% of nonpregnant adults (31,37).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CV CONSEQUENCES OF OVERT AND SCH
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The attributable risk for AF was 41.5% in these patients, and it was not altered by the presence of existing CV disease or other CV risk factors (85).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CARDIOVASCULAR CONSEQUENCES OF OVERT HYPERTHYROIDISM AND SHyper
What the sources say
- Not checked yetcites [85] Collet, 2012, Subclinical hyperthyroidism and the risk of coronary heart disease and mortality, Arch Intern Med source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Hyperthyroid patients may also have higher von Willebrand antigen levels compared with euthyroid patients, leading to enhanced platelet plug formation, which decreases after treatment (60).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH AND THROMBOGENESIS.
What the sources say
- Not checked yetcites [60] Homoncik, 2007, Altered platelet plug formation in hyperthyroidism and hypothyroidism, J Clin Endocrinol Metab source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Another study showed decreased antithrombin III activity and increased levels of fibrinogen, factor VII, and plasminogen activator inhibitor antigen in SCH patients to explain a potential hypercoagulable state (67).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH AND THROMBOGENESIS.
What the sources say
- Not checked yetcites [67] Cantürk, 2003, Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism, Thyroid source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In summary, both TH deficiency and excess can alter the coagulation pathway, although the precise clinical relevance of this finding is unclear (Table 2).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH AND THROMBOGENESIS.
What the sources say
- Not checked yetcites (Table 2)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“TH is a regulator of the tumor suppressor p53, which is activated during AMI, enhancing the mitochondrial apoptosis pathway (21).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [21] de Castro, 2016, Thyroid hormones improve cardiac function and decrease expression of pro-apoptotic proteins in the heart of rats 14 days after infarction, Apoptosis source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A rapid but transient decrease in serum TH concentrations occurs immediately after AMI (114), with maximal changes between 24 h and 36 h after the onset of pain.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
What the sources say
- Not checked yetcites [114] Friberg, 2002, Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina?, Arch Intern Med source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“It is an iodinated derivative of benzofuran and is structurally similar to TH”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > MODULATION OF TH LEVELS BY DRUGS AND ITS IMPACT ON CV SYSTEM AMIODARONE.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“each molecule of the drug containing 2 iodine atoms, whereas T 4 has 4 and T 3 has 3 iodine atoms”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > MODULATION OF TH LEVELS BY DRUGS AND ITS IMPACT ON CV SYSTEM AMIODARONE.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Overall, the experimental and observational findings mentioned previously are in contrast to the common interpretation that TH down-regulation after AMI is an adaptive, favorable process that helps in reducing catabolism and energy expenditure (128), and suggests the potential critical role of the thyroid system in cardioprotection in AMI.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
What the sources say
- Not checked yetcites [128] De Groot, 1999, Dangerous dogmas in medicine: the nonthyroidal illness syndrome, J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“SCH and SHyper, in contrast, occur in 6% and 3% of HF patients, respectively (129).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > TH IN HF
What the sources say
- Not checked yetcites [129] Galli, 2010, The role of thyroid hormone in the pathophysiology of heart failure: clinical evidence, Heart Fail Rev source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“As in patients with other chronic illnesses, NTI is also very common in patients with HF, with a prevalence of approximately 20% to 30% (117).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
What the sources say
- Not checked yetcites [117] Passino, 2009, Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure, J Card Fail source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Decreased activation and increased inactivation of TH are the major causes of these changes in the acute phase of NTI, whereas an altered feedback setting at the hypothalamus-pituitary level is more important in the chronic phase of severe illness.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The net result, as documented by histological and functional parameters, is a reduction in myocardial damage and positive reverse left ventricular (LV) remodeling, resulting in a delay, or even absence, of evolution toward post-ischemic irreversible HF.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Clinical trials of TH therapy in AMI patients are underway”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [142] Jabbar, 2015, Thyroxine in acute myocardial infarction (ThyrAMI) - levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol for a randomised controlled trial, Trials source
- Not checked yetcites [143] Mourouzis, 2011, Thyroid hormone and cardiac disease: from basic concepts to clinical application, J Thyroid Res
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This favors p53 accumulation, and therefore enhances mitochondrial dysfunction and bcl-2-like protein 4 activation, resulting in extended myocardial cell loss (22).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [22] Li, 2010, miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway, PLoS Genet source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Furthermore, a retrospective observational study showed that treatment of SCH with levothyroxine was associated with fewer ischemic heart disease events in younger individuals, but this was not evident in older people (102).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CV CONSEQUENCES OF OVERT AND SCH
What the sources say
- Not checked yetcites [102] Razvi, 2012, Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality, Arch Intern Med source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“As low levels of TH are associated with a decreased metabolic rate”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“TSH levels may rise briefly after the onset of disease, but despite the drop in serum T 3 (and in severe illness also T 4 ) levels, circulating TSH usually remains within the low to normal range.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“NTI occurs in 15% to 20% of patients with AMI (112,113).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
What the sources say
- Not checked yetcites [112] Özcan, 2014, Sick euthyroid syndrome is associated with poor prognosis in patients with ST segment elevation myocardial infarction undergoing primary percutaneous intervention, Cardiol J source
- Not checked yetcites [113] Li, 2011, Negative association between free triiodothyronine level and international normalized ratio in euthyroid subjects with acute myocardial infarction, Acta Pharmacol Sin source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“in patients with post-ischemic HF, p53-responsive microRNA (miR-192, miR-194, and miR-34a) levels are elevated in the early phase of AMI and are positively correlated with LV diastolic dimension (24).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [24] Matsumoto, 2013, Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction, Circ Res source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“THs have a role in cardioprotection due to activation of cytoprotective mechanisms, stimulation of cell growth, neoangiogenesis, and metabolic adaptation.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“T 3 treatment preserves the expression of hypoxia-inducible factor 1-alpha, whose protective effect against reperfusion injury is mediated by inhibiting the mitochondrial opening of the permeability transition pore (26).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [26] Pantos, 2007, Enhanced tolerance of the rat myocardium to ischemia and reperfusion injury early after acute myocardial infarction, Basic Res Cardiol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These changes are due to increased inactivation of TH by the inactivating enzyme deiodinase 3 (D3) and decreased activation by D1 and D2 activity (115,116)”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > INTERPLAY BETWEEN NONTHYROIDAL ILLNESS AND CV DISEASE
What the sources say
- Not checked yetcites [115] Olivares, 2007, Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study, Endocrinology source
- Not checked yetcites [116] Wassen, 2002, Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure, Endocrinology source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“there is a lack of consensus on what constitutes the “normal” upper limit of TSH leading to controversy on definition, prevalence and clinical significance of SCH (89).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [89] Hamilton, 2008, Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism, J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“SCH can also impair relaxation of vascular smooth muscle cells, inducing increases in systemic vascular resistance and arterial stiffness, as well as changes in endothelial function by reduction of nitric oxide availability, without apparent clinical significance (92).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [92] Owen, 2007, Thyroid disease and vascular function, Thyroid source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No interventional studies of TH replacement in AMI patients have been published to date, therefore making a causal relationship between thyroid dysfunction and outcomes difficult to ascertain.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Echocardiographic data indicate that short-term hyperthyroidism induces positive CV changes by improving LV systolic function and enhancing LV relaxation (diastolic flow velocities and isovolumic relaxation time)(72).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [72] Palmieri, 2004, Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade, Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The stated prevalence of SCH in published reports ranges from 4% to 10% of the adult population, being more common in women and older individuals (31,37).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar to overt hyperthyroidism, patients with SHyper may have an increased risk of AF, HF, and CV disease.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Low T 3 syndrome (an isolated reduction of serum T 3 levels with normal T 4 and TSH concentrations) after AMI is observed in up to 1 in 5 patients (114), whereas SCH is observed in almost 12% (127).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [114] Friberg, 2002, Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina?, Arch Intern Med source
- Not checked yetcites [127] Ertugrul, 2011, Prevalence of subclinical hypothyroidism among patients with acute myocardial infarction, ISRN Endocrinol source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“was first shown in a rat model of right ventricular (RV) hypertrophy and failure, where D3 activity increased in the chronically overloaded RV, with no change of activity in the LVs of the same hearts (116).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [116] Wassen, 2002, Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure, Endocrinology source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“patients with moderate hypothyroidism had decreased fibrinolytic activity and were more susceptible to clot formation, whereas patients with severe hypothyroidism had increased fibrinolysis and lower tissue plasminogen activator antigen(65).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [65] Chadarevian, 2001, Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism, J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Both hyper-and hypothyroidism can occur with amiodarone therapy.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This change in T 3 -dependent gene expression was independent of the circulating T 3 concentration in mice, showing that pathological ventricular remodeling after AMI leads to high and stable induction of D3 activity in cardiomyocytes, resulting in a subsequent local hypothyroid condition.”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [118] Pol, 2011, Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition, Endocrinology source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“ameliorating oxidative stress with antioxidants prevents the acute reduction of serum T 3 levels in patients with AMI, although it is unknown if this has any effect on cardiac function or outcomes (126).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [126] Vidart, 2014, N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial, J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The degree of TH down-regulation is associated with higher impairment of cardiac function and higher inflammatory response (114,121).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [114] Friberg, 2002, Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina?, Arch Intern Med source
- Not checked yetcites [121] Kimur, 2001, Correlation of circulating interleukin-10 with thyroid hormone in acute myocardial infarction, Res Commun Mol Pathol Pharmacol
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The induction of D3 is localized in cardiomyocytes only and is associated with a substantial decrease in tissue T 3 concentrations and T 3 -dependent gene expression (118).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [118] Pol, 2011, Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition, Endocrinology source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Studies investigating coagulation in overt hypothyroidism have yielded conflicting results, with 2 studies showing hypercoagulability (62,63) and 1 study showing increased fibrinolysis (64).”
§ THE PRESENT AND FUTURE STATE-OF-THE-ART REVIEWS Thyroid Hormones and Cardiovascular Function and Diseases > CONCLUSIONS
What the sources say
- Not checked yetcites [62] Squizzato, 2005, Thyroid diseases and cerebrovascular disease, Stroke source
- Not checked yetcites [63] Erem, 2003, Blood coagulation and fibrinolytic activity in hypothyroidism, Int J Clin Pract source
- Not checked yetcites [64] Gullu, 2005, Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism, Eur J Endocrinol source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Thyroid hormone receptors are present in the myocardium and vascular tissue.
“Thyroid hormone (TH) receptors (TRs) are present in myocardium and vascular endothelial tissues”
“Thyroid hormone (TH) receptors are present in the myocardium and vascular tissue”
The paper relies on this without support.
Thyroid function is regulated by the hypothalamic-pituitary-thyroid axis through a classic endocrine feedback loop.
“Thyroid function is regulated by the hypothalamic-pituitary-thyroid axis via a classic endocrine feedback loop mechanism.”
The paper relies on this without support.
Thyrotropin-releasing hormone is secreted by the hypothalamus and stimulates the anterior pituitary to produce thyroid-stimulating hormone, which drives the thyroid gland to release thyroid hormone.
“Thyrotropin-releasing hormone (TRH) is secreted at the level of the hypothalamus and stimulates the anterior pituitary to produce thyroid-stimulating hormone (TSH), which, in turn, drives the thyroid gland to release TH.”
The paper relies on this without support.
Amiodarone contains iodine, and a 200-mg tablet contains 500 times more iodine than the average daily requirement.
“Amiodarone contains iodine, and a 200-mg tablet contains 500 times more iodine than the average daily requirement”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nevertheless, it is important to recognise and treat as it is associated with adverse cardiovascular outcomes if left untreated long term.87”
From Hypothyroidism (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredIn the citing paper
“Thyroid hormones exert a direct action at the cardiac level through the combination of genomic and non-genomic effects, ultimately contributing to the regulation of cardiac function and CV hemodynamics [5].”
From Thyroid and heart, a clinically relevant relationship (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
CHD risk is called significant despite a confidence interval that includes 1
MinorThe stated 95% confidence interval for the CHD-events hazard ratio runs from 0.99 to 1.46. Because it includes 1, that estimate does not support the claim of a statistically significant increase in CHD events.
“In age-and sex-adjusted analyses, these risks were significantly higher in participants with grade 2 SHyper”
“HR: 1.21; 95% CI: 0.99 to 1.46 for CHD events”
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117 · cited 1×
“Recurrent ischemia resulting in adverse CV events following optimal treatment for an acute coronary syndrome occurs in approximately 10% of subjects in randomized controlled trials (RCTs) (2), and this number nearly doubles in real-world registries (3).”
BackgroundRoss, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., et al. (2016) · Thyroid® · doi:10.1089/thy.2016.0229 · Cited by 2,938
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
Self-citationHak, A. E., Pols, H. A. P., Visser, T. J., Drexhage, H. A., Hofman, A., & Witteman, J. C. M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00004 · Cited by 1,336
Klein, I., & Danzi, S. (2007) · Circulation · doi:10.1161/circulationaha.106.678326 · Cited by 1,324
Self-citationCooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039
Self-citationA family of microRNAs encoded by myosin genes governs myosin expression and muscle performance
van Rooij, E., Quiat, D., Johnson, B. A., Sutherland, L. B., Qi, X., Richardson, J. A., Kelm, R. J., & Olson, E. N. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.10.013 · Cited by 960
Thyroid Status, Disability and Cognitive Function, and Survival in Old Age
Gussekloo, J. (2004) · JAMA · doi:10.1001/jama.292.21.2591 · Cited by 899
Mann, D. L., Zipes, D. P., Libby, P., Bonow, R. O., & D, E. B. M. (2015) · Elsevier eBooks · Cited by 882
Flagged first, then by citations
3 of the 145 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Klein, 2014, Chapter 81: Endocrine disorders and cardiovascular disease, 1793
Cited by
Sorted by citations
Items 101–200 of 512
Han, Y., Wang, C., Zhang, L., Zhu, J., Zhu, M. J., Li, Y., Teng, D., Teng, W., & Shan, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.853889 · Cited by 15
Significant cardiac disease complicating Graves’ disease in previously healthy young adults
Witczak, J., Ubaysekara, N., Ravindran, R., Rice, S., Yousef, Z. R., & Premawardhana, L. D. K. E. (2020) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0132 · Cited by 14
Nakanishi, K., Daimon, M., Yoshida, Y., Sawada, N., Hirose, K., Iwama, K., Yamamoto, Y., Ishiwata, J., Hirokawa, M., Kaneko, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa730 · Cited by 14
Lorigo, M., Quintaneiro, C., Breitenfeld, L., & Cairrão, E. (2021) · Biomedicines · doi:10.3390/biomedicines9020115 · Cited by 14
Low T3 syndrome predicts more adverse events in patients with hypertrophic cardiomyopathy
He, C., Zhu, C., Fan, H., Qian, Y., Zhai, C., & Hu, H. (2023) · Clinical Cardiology · doi:10.1002/clc.24156 · Cited by 15
Subclinical Hyperthyroidism and Cardiovascular Disease
Kim, H. J., & McLeod, D. S. A. (2024) · Thyroid · doi:10.1089/thy.2024.0291 · Cited by 15
Bao, M., Hua, X., Mo, H., Sun, Z., Xu, B., Chen, X., Xu, M., Xu, X., & Song, J. (2022) · Biomolecules · doi:10.3390/biom12091195 · Cited by 12
Li, M., Zhang, X., Zhou, X., Han, X., Zhang, R., Fu, Z., Wang, L., Gao, Y., Li, Y., & Ji, L. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s252154 · Cited by 13
Niedowicz, D. M., Wang, W., PRICE, D. A., Xie, K., Patel, E., & Nelson, P. T. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.04.012 · Cited by 10
Hypothyroidism, comorbidity and health-related quality of life: a population-based study
Wouters, H. J. C. M., Wolffenbuttel, B. H. R., Kobold, A. C. M., Links, T. P., Huls, G. A., & van der Klauw, M. M. (2023) · Endocrine Connections · doi:10.1530/ec-23-0266 · Cited by 12
Baretella, O., Blum, M. R., Abolhassani, N., Alwan, H., Wildisen, L., Giovane, C. D., Tal, K., Moutzouri, E., Åsvold, B. O., Cappola, A. R., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae860 · Cited by 20
Self-citationRole of miR-133/Dio3 Axis in the T3-Dependent Modulation of Cardiac mitoK-ATP Expression
Canale, P., Nicolini, G., Pitto, L., Kusmic, C., Rizzo, M., Balzan, S., Iervasi, G., & Forini, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126549 · Cited by 11
Self-citationZhu, Q., Jiang, G., Lang, X., Zhang, J., Fu, Z., Zhang, P., Zheng, Y., & Zhang, X. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.103 · Cited by 11
Sýkora, M., Bačová, B. S., Beňová, T. E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153758 · Cited by 12
A practical contemporary approach to decision-making on subclinical hypothyroidism
Sgarbi, J. A., & Ward, L. S. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000317 · Cited by 15
Comorbidities of hypothyroidism
Brenta, G., & Gottwald‐Hostalek, U. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2476075 · Cited by 15
Polymorphisms of DNA Repair Genes in Thyroid Cancer
Gielecińska, A., Kciuk, M., Kołat, D., Kruczkowska, W., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115995 · Cited by 10
Doğduş, M., DİKER, S., Yenerçağ, M., & Gürgün, C. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-020-02011-3 · Cited by 10
Gu, Y., Meng, G., Qing, Z., Liu, L., Wu, H., Zhang, S., Wang, Y., Zhang, T., Wang, X., Sun, S., et al. (2021) · Age and Ageing · doi:10.1093/ageing/afab276 · Cited by 12
Brain nuclear receptors and cardiovascular function
Wang, M., Yang, Y., & Xu, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00962-3 · Cited by 12
Lang, X., Zhao, B., Fang, S., Li, L., Li, Z., Wu, N., Zhang, Y., Li, Y., Li, Y., & Zhang, Y. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad240 · Cited by 10
Pingitore, A., Mastorci, F., Berti, S. L., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225267 · Cited by 10
Self-citationElmenyar, E., Aoun, S., Saadi, Z. A., Barkumi, A., Cander, B., Al-Thani, H. A. S., & El-Menyar, A. A. (2023) · Diagnostics · doi:10.3390/diagnostics13193028 · Cited by 11
Huang, L., Luo, Y. H., Chen, Z.-L., Yang, Z., & Wu, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21694 · Cited by 10
Qin, Z., Muhanhali, D., & Ling, Y. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad735 · Cited by 12
Murray, M.-I. K., Bode, K., & Whittaker, P. (2019) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2019.09.004 · Cited by 11
Hypothyreose: Guidelines, neue Erkenntnisse und klinische Praxis
Pilz, S., Theiler‐Schwetz, V., Malle, O., Steinberger, E., & Trummer, C. (2020) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-020-00114-9 · Cited by 10
Links, T. P., van der Boom, T., Zandee, W. T., & Lefrandt, J. D. (2020) · Endocrine Connections · doi:10.1530/ec-20-0539 · Cited by 10
Wei, S., Shu, Z., Li, X., Zhong, S., Xiao, L., Shen, R., Lu, X., He, L., Zhang, Y., Quan, Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156452 · Cited by 11
Association of stress and primary hypothyroidism
Singh, M., Narayan, J., Thakur, R., Bhattacharya, S., Sonkar, S. K., & Ali, W. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_845_23 · Cited by 10
Couto, B., Neves, C., Neves, J. S., & Delgado, L. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01765-4 · Cited by 9
Pohl, K. R., Hobohm, L., Krieg, V. J., Sentler, C., Rogge, N. I. J., Steimke, L., Ebner, M., Lerchbaumer, M. H., Hasenfuss, G. P., Konstantinides, S., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.01.014 · Cited by 7
Du, J., Zhao, X., Xu, X., Zhang, Z., & Zhang, X. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s429941 · Cited by 9
Thyroid Disorders and Peripheral Arterial Disease
Studen, K. B., Gaberšček, S., Zaletel, K., Blinc, A., Šabović, M., Schernthaner, G.-H., Anagnostis, P. G., Antignani, P. L., Jensterle, M., Mikhailidis, D. P., et al. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611271284231105063148 · Cited by 9
Pakdel, R., Vatanchian, M., Niazmand, S., et al. (2019) · Drug and Chemical Toxicology · doi:10.1080/01480545.2019.1651330 · Cited by 9
Relation Between Thyroid Function and Mortality in Patients With Chronic Heart Failure
Samuel, N. A., Cuthbert, J. J., Brown, O. I., Kazmi, S., Cleland, J. G. F., Rigby, A. S., & Clark, A. L. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.10.034 · Cited by 9
Triiodothyronine alongside levothyroxine in the management of hypothyroidism?
Gottwald-Hostalek, U., & Kahaly, G. J. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1984219 · Cited by 9
Dell'Aquila, M., Rossi, C. S., Caldonazo, T. M. M., Cancelli, G., Harik, L., Soletti, G. J., An, K. R., Leith, J., Kirov, H., Ibrahim, M., et al. (2024) · JTCVS Open · doi:10.1016/j.xjon.2024.02.009 · Cited by 10
Cardiovascular mechanisms of thyroid hormones and heart failure: Current knowledge and perspectives
Čulić, V. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i5.226 · Cited by 9
Thyroid dysfunction and cardiovascular disease
Alwan, H., Hysaj, O., Gencer, B., Duntas, L. H., & Rodondi, N. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag248 · Cited by 15
Razvi, S., Leng, O., Jabbar, A., Bano, A., Ingoe, L. E., Addison, C., Thomas, H. E., Carey, P. E., Junejo, S., Austin, D., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz143 · Cited by 8
Self-citationWisnu, W., Alwi, I., Nafrialdi, N., Harimurti, K., Pemayun, T. G. D., Jusman, S. W. A., Santoso, . I. S., Harahap, A. R., Suwarto, S., & Subekti, I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.796194 · Cited by 8
Thyroid dysfunction and mortality in cardiovascular hospitalized patients
Frankel, M., Bayya, F., Munter, G., Wolak, A., Tolkin, L., Barenhoz-Goultschin, O., Asher, E., & Glikson, M. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000299 · Cited by 8
Tsare, E.-P. G., Klapa, M. I., & Moschonas, N. Κ. (2024) · Human Genomics · doi:10.1186/s40246-023-00565-6 · Cited by 9
Thyroid hormone: a resurgent treatment for an emergent concern
Breitzig, M., Alleyn, M. D., Lockey, R. F., & Kolliputi, N. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00336.2018 · Cited by 7
Wells, M. A., Hoe, L. E. S., Heather, L. C., Molenaar, P., Suen, J. Y., Peart, J. N., McGiffin, D. C., & Fraser, J. F. (2020) · Transplantation · doi:10.1097/tp.0000000000003368 · Cited by 10
Beta‐arrestin 2 mediates cardiac hypertrophy induced by thyroid hormones via AT1R
Lino, C. A., Teixeira, L. B., Simões, S. C., Silva, T. D. O., Diniz, G. P., Costa-Neto, C. M., & Barreto‐Chaves, M. L. M. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30187 · Cited by 8
Graves’ Disease and the Risk of End-Stage Renal Disease: A Korean Population-Based Study
Cho, Y. Y., Kim, B., Shin, D. W., et al. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1333 · Cited by 8
Endocrine hormone imbalance in heart failure with reduced ejection fraction: A cross‐sectional study
Nägele, M. P., Barthelmes, J., Kreysing, L., Haider, T., Nebunu, D., Ruschitzka, F. T., Sudano, I., & Flammer, A. J. (2022) · Health Science Reports · doi:10.1002/hsr2.880 · Cited by 8
Tafese, R., Genet, S., & Addisu, S. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s391777 · Cited by 7
Gürdoğan, M., Altay, S., Korkmaz, S., Kaya, Ç., Zeybey, U., Ebik, M., & Demir, M. (2019) · Medicina · doi:10.3390/medicina55050175 · Cited by 8
Wu, T., Wang, C., Tien, N., Lin, C., Chu, F.-Y., Chang, H., & Lim, Y.-P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00228 · Cited by 9
Prognostic value of free triiodothyronine in patients with dilated cardiomyopathy
Zhao, H., Sun, L. V., Zhu, Y., Chen, Q.-S., Zhu, W., Toorabally, M. B., Chen, X., & Zhang, F. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000896 · Cited by 8
Neves, J. S., Leite, A. R., Conceição, G., Gonçalves, A., Borges‐Canha, M., Vale, C., von Hafe, M., Martins, D., Miranda‐Silva, D., Leite, S., et al. (2023) · Thyroid · doi:10.1089/thy.2022.0717 · Cited by 7
Zhou, Y., He, Q., Ai, H., Zhao, X., Chen, X., Li, S., Zhang, Z., Fan, J., Gong, W., & Nie, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1451645 · Cited by 7
Association between atherosclerosis and the development of multi-organ pathologies
Dabravolski, S. A., Churov, A. V., Elizova, N. V., Ravani, A. L., Karimova, A. E., Sukhorukov, V. N., & Orekhov, A. N. (2024) · SAGE Open Medicine · doi:10.1177/20503121241310013 · Cited by 8
Wang, F., Zhang, X., Hu, Y., Wang, G., Pi, J., Wang, T., Guo, H., Zhang, M., Zhang, L., & Xu, Y. (2025) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2025.114574 · Cited by 8
Hypothyroidism: playing the cardiometabolic risk concerto
Kahaly, G. J., Liu, Y., & Persani, L. (2025) · Thyroid Research · doi:10.1186/s13044-025-00233-y · Cited by 11
Kidney diseases and the thyroid: interactions and consequences
Brenta, G. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01203-y · Cited by 7
Associations of Thyroid Hormones and Resting Heart Rate in Patients Referred to Coronary Angiography
Steinberger, E., Pilz, S., Trummer, C., Theiler‐Schwetz, V., Reichhartinger, M., Benninger, T., Pandis, M., Malle, O., Keppel, M. H., Verheyen, N., et al. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1232-7292 · Cited by 7
Low T3 syndrome is associated with 30-day mortality in adult patients with fulminant myocarditis
Miao, G., Pang, S., Zhou, Y., Duan, M., Bai, L., & Zhao, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1164444 · Cited by 7
Comparative effects of amiodarone and dronedarone treatments on cardiac function in a rabbit model
Boonhoh, W., Kijtawornrat, A., & Sawangkoon, S. (2019) · Veterinary World · doi:10.14202/vetworld.2019.345-351 · Cited by 6
Ohba, K., & Iwaki, T. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0177 · Cited by 9
Peripubertal soy isoflavone consumption leads to subclinical hypothyroidism in male Wistar rats
Forno, G. O. D., de Oliveira, I. M., Cavallin, M. D., Santos, T. I. A., Sleiman, H. K., Falbo, M. K., Romano, M. A., & Romano, R. M. (2022) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174422000496 · Cited by 6
Influencia del hipotiroidismo e hipertiroidismo en el desarrollo de enfermedad cardiovascular
Gordillo Iñiguez, A. M., & Mogrovejo Palacios, D. R. (2020) · Revista Médica-Científica CAMbios HECAM · doi:10.36015/cambios.v18.n2.2019.533 · Cited by 7
Liu, Q., Chen, L., Liu, X., Peng, G., Zhong, X., Sheng, Y., Luo, S., Huang, Y., Xu, J., & Liu, Y. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-534 · Cited by 7
Tian, Y., Yao, D., Jin, A., Wang, M., Pan, Y., Wang, Y., & Wang, Y. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad114 · Cited by 8
Circulating thyroid hormones and clinical parameters of heart failure in men
Turić, I., Velat, I., Bušić, Ž., & Čulić, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-47391-3 · Cited by 7
Марущак, М. І. (2021) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.03.20 · Cited by 8
Protective role of vitamin D3 in a rat model of hyperthyroid-induced cardiomyopathy
Salem, H. R., Hegazy, G. A., Abdallah, R., & Abo-Elsoud, R. A. A. (2023) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2023.02.007 · Cited by 8
Treatment of subclinical hypothyroidism: assessing when treatment is likely to be beneficial
Leng, O., & Razvi, S. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1738924 · Cited by 7
Self-citationThe role of deiodinases on metabolic alteration in cancer
Miro, C., Cicatiello, A. G., Dentice, M., & Nappi, A. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.003 · Cited by 7
Adipocyte RNA-binding protein CELF1 promotes beiging of white fat through stabilizing Dio2 mRNA
Zeng, T., Xiao, L., Li, J., Wu, H., Guo, X., Zhu, F., Yu, X., Cui, Y., Zhao, X., Wang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62740-8 · Cited by 6
Circadian determinants of heart rhythm and arrhythmias
Boyett, M. R., Li, P., Xiang, Y., Zhang, H., Kim, J. K., & D’Souza, A. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.08.012 · Cited by 8
Arterial Stiffness in Thyroid and Parathyroid Disease: A Review of Clinical Studies
Grillo, A., Barbato, V., Antonello, R. M., Cola, M. F., Parati, G., Salvi, P., Fabris, B., & Bernardi, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113146 · Cited by 7
Renal function changes in patients with subclinical hyperthyroidism: a novel postulated mechanism
Allam, M. M., El‐Zawawy, H. T., & Elzawawy, T. H. (2023) · Endocrine · doi:10.1007/s12020-023-03361-3 · Cited by 6
Fang, X., Hu, R., Fei, S., Ding, Z., Zhao, J., & Shang, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1437386 · Cited by 6
Li, J., Wang, Y., Luo, X., Meng, T., Li, C., Li, J., & Du, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1402359 · Cited by 6
Age and Sex Influence Thyroid Hormone Effects in Target Tissues with Organ-Specific Responses
Kerp, H., Gassen, J., & Führer, D. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1083-6272 · Cited by 7
Barisón, M. J., Pereira, I. T., Robert, A. W., & Dallagiovanna, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031330 · Cited by 7
Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma
Xue, L.-G., Shen, H.-R., Gao, R., Du, K., Xing, T., Wang, W., Wang, L., Li, J., Liang, J., & Xu, W. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05117-5 · Cited by 6
Abasilim, C., Persky, V., Sargis, R. M., Argos, M., Daviglus, M. L., Freels, S. A., Tsintsifas, K., Day, T., Cai, J., Isasi, C. R., et al. (2023) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-023-01762-8 · Cited by 5
Liu, L., Zeng, B., Zhang, J., Li, G., & Zong, W. (2023) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2023.2279421 · Cited by 6
Thyroid and Heart: A Fatal Pathophysiological Attraction in a Controversial Clinical Liaison
Pingitore, A., Mastorci, F., Lazzeri, M. F. L., & Vassalle, C. (2023) · Endocrines · doi:10.3390/endocrines4040053 · Cited by 7
Self-citationSong, J., Hu, J., Li, L., Xu, Z., Li, J., Sun, S., & Chen, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1323994 · Cited by 6
Thyroid cancer and cardiovascular diseases: a Mendelian randomization study
Gao, Y. S., Wang, Z., Yu, J., & Chen, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1344515 · Cited by 6
Management of Dyslipidemia in Endocrine Diseases
Tannock, L. R. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.003 · Cited by 8
Thyroid storm-induced cardiovascular complications and modalities of therapy: Up-to-date review
El-Menyar, A. A., Khan, N. A., Elmenyar, E., Cander, B., Szarpak, Ł., Vimal Krishnan, S., Galwnkar, S., & Al-Thani, H. A. S. (2025) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v14.i4.109565 · Cited by 7
Convergent Metabolic Pathways in MASH Therapeutics: An AMPK ‐Centric Analysis
Choi, S., Jung, J., Seo, Y., Song, S., Ham, J., Chung, H., Ramadan, Y., & Choi, K. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71023 · Cited by 5
Subclinical Hypothyroidism, Kidney, and Heart from Normal to Uremic Milieu
Spahia, N., Rroji, M., Barbullushi, M., & Spasovski, G. B. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0057 · Cited by 5
Local DIO2 Elevation Is an Adaption in Malformed Cerebrovasculature
Li, R., Tang, Y., Wang, H., Hu, P., Yu, L., Lv, C., Zhang, Y., Gerdes, A. M., & Wang, Y. (2025) · Circulation Research · doi:10.1161/circresaha.124.325857 · Cited by 5
Physiological and Pathological Cardiac Remodeling in Altered Thyroid Hormone States
Rajagopalan, V., & Gerdes, A. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-36871-5_11 · Cited by 4
Lipidomic Perturbations in Cynomolgus Monkeys are Regulated by Thyroid Stimulating Hormone
Xu, T., Yang, Y., Huang, X., Ren, J., Xu, T., & Xie, W. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.640387 · Cited by 5
Zhu, Y., Shen, J., Xue, Y., Xiang, Z., Jiang, Y., Zhou, W., & Luo, S. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s333322 · Cited by 5
CaMKII inhibition protects against hyperthyroid arrhythmias and adverse myocardial remodeling
Nie, D., Xia, C., Wang, Z., Ding, P., Meng, Y., Liu, J., Li, T., Gan, T., Xuan, B., Huang, Y. L., et al. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.082 · Cited by 5
[Retracted] Effect of Radioimmunoassay on Accuracy of Thyroid Hormone Detection
Wu, Z. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/9206079 · Cited by 5
RetractedChen, W., Wang, W., Ding, C., et al. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104718 · Cited by 5
Alhowail, A. H., & Aldubayan, M. A. (2023) · Pharmaceuticals · doi:10.3390/ph16091312 · Cited by 5
Blood pressure in hyperthyroid cats before and after radioiodine treatment
Stammeleer, L., Xifra, P., Serrano, S. I., Rishniw, M., Daminet, S., & Peterson, M. E. (2024) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.17032 · Cited by 5
Dore, R., Sentis, S. C., Johann, K., López‐Alcántara, N., Resch, J., Chandrasekar, A., Müller‐Fielitz, H., Moeller, L. C., Fuehrer, D., Schwaninger, M., et al. (2024) · Thyroid · doi:10.1089/thy.2023.0638 · Cited by 6
Metadata
- Authors
- Razvi, S., Jabbar, A., Pingitore, A., Danzi, S., Biondi, B., Klein, I., Peeters, R., Zaman, A., & Iervasi, G.
- Affiliations
- Gateshead Health NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Istituto di Fisiologia Clinica (IT)
- City University of New York (US)
- Federico II University Hospital (IT)
- New York University (US)
- Erasmus MC (NL)
- Corresponding author
- Razvi, Salman
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 71
- Issue
- 16
- Pages
- 1781-1796
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2800239085
- Semantic Scholar
- 0878483096883b7de0e4d27ed98bab6d94a1b5fc
- Cited by
- 515
- References
- 145
- Citations by year
- 2026: 62 · 2025: 69 · 2024: 84 · 2023: 68 · 2022: 74 · 2021: 58 · 2020: 69 · 2019: 29 · 2018: 2
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by-nc-nd)
- Funders
- National Institute for Health and Care Research (CDF-2012-05-231)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- thyroid hormones, thyroid hormone receptor, cardiovascular disease, thyroid dysfunction, endothelial dysfunction, blood pressure, diastolic dysfunction, dyslipidemia, low triiodothyronine syndrome, thyroid hormone replacement
- MeSH terms
- Heart Diseases, Humans, Hyperthyroidism, Risk Factors, Thyroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review